Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A real-world study shows belzutifan dramatically reduces the need for tumor reduction procedures in patients with Von Hippel-Lindau (VHL) disease. After starting the drug, patients saw a 58% overall drop in procedures — including a 70% reduction in brain tumor surgeries. Most patients also stayed on therapy long-term, underscoring the drug's durability in managing this rare genetic condition.
A new real-world study presented at IKCS: North America 2026 confirms that belzutifan — an FDA-approved treatment for Von Hippel-Lindau (VHL) disease — significantly cuts the need for tumor reduction procedures (TRPs) while keeping patients on therapy long-term. Researchers analyzed administrative claims data from 237 VHL patients who started belzutifan after its August 2021 FDA approval, comparing procedure rates in the 24 months before and after treatment initiation.
The results were striking: belzutifan slashed the overall rate of TRPs by 58%, with even steeper reductions in specific procedure types. Notably, 60% of patients were still on the drug at the two-year mark, and nearly half of those who paused treatment eventually restarted it.
By the Numbers:
Why it matters: VHL disease is a rare genetic disorder that causes tumors to grow in multiple organs, often requiring repeated surgeries. These findings add meaningful real-world evidence that belzutifan not only reduces the surgical burden for patients but also sustains long-term disease management — a significant quality-of-life win for a population that has historically faced relentless tumor recurrence.